Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

umor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data of VELCADE as a single-agent: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients re
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), ... tissue and patent-protected processes to develop and market ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... multiple inaccuracies in the press release issued by ... rulings from the Patent Trial and Appeal Board ...
(Date:8/27/2015)... the leading innovation partner to companies worldwide , ... and anticipates the creation of over 350 new jobs through ... In 2013, the State of Ohio ... to accelerate adoption of open innovation among Ohio ... revenues. To date over 45 middle market companies have worked ...
(Date:8/27/2015)... 27, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Morgan Stanley Global Healthcare Conference on September ... are invited to listen to the live discussion via ... directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded ... after the conclusion of the live event and accessible ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3
... N.J. , May 27 Tibotec Therapeutics, a ... launch of the HIV Case Manager Portal (the ... designed to help HIV/AIDS front-line service providers meet their daily ... in Denver, CO at the 22nd National Conference ...
... May 26 Results of clinical studies ... Staccato® loxapine (AZ-004) reduced agitation in patients, regardless of ... levels were observed as early as 10 minutes after ... by the Positive and Negative Syndrome Scale - Excited ...
Cached Medicine Technology:Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 2Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 4Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 2Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 3Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 4Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 5Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 6Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 7Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 8
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Northridge dentists ... Zoom teeth whitening. For just $199, patients can currently receive a one hour treatment ... teeth whitening procedures, but it includes a number of unique features that can turn ...
(Date:8/28/2015)... Raleigh, NC (PRWEB) , ... August 28, 2015 , ... ... mesothelioma will not be available for general use any time soon, according to educational ... MTG-201, a biologic therapy that received orphan drug designation for mesothelioma last week from ...
(Date:8/28/2015)... MO (PRWEB) , ... August 28, 2015 , ... ... testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement Therapy Products ... a cap on the number of custodial files the PSC may receive for ...
(Date:8/28/2015)... ... August 28, 2015 , ... An independent ... result in high percentages of change to treatment recommendations and diagnosis. The 2015 ... at Tennessee Tech University and analyzed WorldCare’s second opinion process. , The study ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... do not get training posts through the flawed Medical ... the government// is stalling on a new contract for ... figures show that 34,250 doctors are chasing 18,500 specialist ... far given no commitment that trainee doctors will be ...
... promising anti-inflammatory drug failed to improve symptoms of moderate ... a large, multi-center trial. ,The results ... published in the first issue of the May American ... the American Thoracic Society. ,According to an ...
... a heart attack or severe chest pain today are much less ... even a few years ago, according to a new international study. ... a significant drop in the rate of heart failure and death ... ,The study finds that the change occurred at the same time ...
... war veterans who have come back after combat in the ... chemicals and other harmful substances, there is a decreased volume ... and memory. ,Roberta White, chair of the department ... Health, revealed, at the American Academy of Neurology's 59th Annual ...
... alert following a malaria epidemic that has claimed at ... ,"Doctors and paramedics have been put on alert ... out to vulnerable areas to check the spread of ... ,Eight of Assam's 29 districts have been ...
... immediately spot the victims of a bite from the Brazilian ... and an increase in blood pressure, they also sport an ... quest for more Viagras. Scientists say they have figured out ... boost. , “The erection is a side effect ...
Cached Medicine News:Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Gulf War Veterans Exhibit Memory Impairment 2Health News:Malaria Claims 25 Lives in Assam 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: